Psoriasis is a chronic, immune-mediated, inflammatory disease primarily affecting the skin. It is currently coming to light that patients with psoriasis have disrupted intestinal barrier and often suffer from comorbidities associated with the gastrointestinal tract. Moreover, there is growing evidence of both cutaneous and intestinal paradoxical reactions during biologic treatment in patients with psoriasis. This review focuses on barrier defects and changes in immune responses in patients with psoriasis, which play an important role in the development of the disease but are also influenced by modern biological treatments targeting IL-17 and TNFα cytokines. Here, we highlight the relationship between the gut-skin axis, microbiota, psoriasis treatment, and the incidence of paradoxical reactions, such as inflammatory bowel disease in patients with psoriasis. A better understanding of the interconnection of these mechanisms could lead to a more personalized therapy and lower the incidence of treatment side effects, thereby improving the quality of life of the affected patients.

Department of Dermatovenerology 2nd Faculty of Medicine Charles University Bulovka University Hospital Prague Czech Republic

Institute of Microbiology of the Czech Academy of Sciences Videnska 1083 14220 Prague Czech Republic

Zobrazit více v PubMed

Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945–1960. doi: 10.1001/jama.2020.4006. PubMed DOI

Tsoi LC, Stuart PE, Tian C, Gudjonsson JE, Das S, Zawistowski M, et al. Large scale meta-analysis characterizes genetic architecture for common psoriasis associated variants. Nat Commun. 2017;8:15382. doi: 10.1038/ncomms15382. PubMed DOI PMC

Roszkiewicz M, Dopytalska K, Szymanska E, Jakimiuk A, Walecka I. Environmental risk factors and epigenetic alternations in psoriasis. Ann Agric Environ Med. 2020;27(3):335–342. doi: 10.26444/aaem/112107. PubMed DOI

Fry L, Baker BS, Powles AV, Engstrand L. Psoriasis is not an autoimmune disease? Exp Dermatol. 2015;24(4):241–244. doi: 10.1111/exd.12572. PubMed DOI

Arakawa A, Siewert K, Stohr J, Besgen P, Kim SM, Ruhl G, et al. Melanocyte antigen triggers autoimmunity in human psoriasis. J Exp Med. 2015;212(13):2203–2212. doi: 10.1084/jem.20151093. PubMed DOI PMC

Boutet MA, Nerviani A, Gallo Afflitto G, Pitzalis C. Role of the IL-23/IL-17 axis in psoriasis and psoriatic arthritis: the clinical importance of its divergence in skin and joints. Int J Mol Sci. 2018;19(2):530. doi: 10.3390/ijms19020530. PubMed DOI PMC

Cheung KL, Jarrett R, Subramaniam S, Salimi M, Gutowska-Owsiak D, Chen YL, et al. Psoriatic T cells recognize neolipid antigens generated by mast cell phospholipase delivered by exosomes and presented by CD1a. J Exp Med. 2016;213(11):2399–2412. doi: 10.1084/jem.20160258. PubMed DOI PMC

Lande R, Botti E, Jandus C, Dojcinovic D, Fanelli G, Conrad C, et al. The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. Nat Commun. 2014;5:5621. doi: 10.1038/ncomms6621. PubMed DOI

Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496–509. doi: 10.1056/NEJMra0804595. PubMed DOI

Singh S, Young P, Armstrong AW. An update on psoriasis and metabolic syndrome: A meta-analysis of observational studies. PLoS ONE. 2017;12(7):e0181039. doi: 10.1371/journal.pone.0181039. PubMed DOI PMC

Sundarrajan S, Arumugam M. Comorbidities of psoriasis—exploring the links by network approach. PLoS ONE. 2016;11(3):e0149175. doi: 10.1371/journal.pone.0149175. PubMed DOI PMC

rob f hj. Komorbidity psoriázy a jejich management. Remedia 2019;1/2019(29):56–60.

Alinaghi F, Calov M, Kristensen LE, Gladman DD, Coates LC, Jullien D, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251–65 e19. doi: 10.1016/j.jaad.2018.06.027. PubMed DOI

Wu JJ, Feldman SR, Koo J, Marangell LB. Epidemiology of mental health comorbidity in psoriasis. J Dermatolog Treat. 2018;29(5):487–495. doi: 10.1080/09546634.2017.1395800. PubMed DOI

Korman NJ. Management of psoriasis as a systemic disease: what is the evidence? Br J Dermatol. 2020;182(4):840–848. doi: 10.1111/bjd.18245. PubMed DOI PMC

Guttman-Yassky E, Nograles KE, Krueger JG. Contrasting pathogenesis of atopic dermatitis and psoriasis—part I: clinical and pathologic concepts. J Allergy Clin Immunol. 2011;127(5):1110–1118. doi: 10.1016/j.jaci.2011.01.053. PubMed DOI

Montero-Vilchez T, Cuenca-Barrales C, Martinez-Lopez A, Molina-Leyva A, Arias-Santiago S. Skin adverse events related to personal protective equipment: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2021;35(10):1994–2006. doi: 10.1111/jdv.17436. PubMed DOI

Sikora M, Chrabaszcz M, Maciejewski C, Zaremba M, Waskiel A, Olszewska M, et al. Intestinal barrier integrity in patients with plaque psoriasis. J Dermatol. 2018;45(12):1468–1470. doi: 10.1111/1346-8138.14647. PubMed DOI

Stehlikova Z, Kostovcik M, Kostovcikova K, Kverka M, Juzlova K, Rob F, et al. Dysbiosis of skin microbiota in psoriatic patients: co-occurrence of fungal and bacterial communities. Front Microbiol. 2019;10:438. doi: 10.3389/fmicb.2019.00438. PubMed DOI PMC

Munz OH, Sela S, Baker BS, Griffiths CE, Powles AV, Fry L. Evidence for the presence of bacteria in the blood of psoriasis patients. Arch Dermatol Res. 2010;302(7):495–498. doi: 10.1007/s00403-010-1065-0. PubMed DOI

Ramirez-Bosca A, Navarro-Lopez V, Martinez-Andres A, Such J, Frances R, Horga de la Parte J, et al. Identification of bacterial DNA in the peripheral blood of patients with active psoriasis. JAMA Dermatol. 2015;151(6):670–1. PubMed

Codoner FM, Ramirez-Bosca A, Climent E, Carrion-Gutierrez M, Guerrero M, Perez-Orquin JM, et al. Gut microbial composition in patients with psoriasis. Sci Rep. 2018;8(1):3812. doi: 10.1038/s41598-018-22125-y. PubMed DOI PMC

Sano S, Chan KS, Carbajal S, Clifford J, Peavey M, Kiguchi K, et al. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat Med. 2005;11(1):43–49. doi: 10.1038/nm1162. PubMed DOI

Maroto-Morales D, Montero-Vilchez T, Arias-Santiago S. Study of skin barrier function in psoriasis: The impact of emollients. Life (Basel). 2021;11(7). PubMed PMC

Montero-Vilchez T, Segura-Fernandez-Nogueras MV, Perez-Rodriguez I, Soler-Gongora M, Martinez-Lopez A, Fernandez-Gonzalez A, et al. Skin barrier function in psoriasis and atopic dermatitis: transepidermal water loss and temperature as useful tools to assess disease severity. J Clin Med. 2021;10(2). PubMed PMC

Fasano A. All disease begins in the (leaky) gut: role of zonulin-mediated gut permeability in the pathogenesis of some chronic inflammatory diseases. F1000Res. 2020;9:69. PubMed PMC

Tlaskalova-Hogenova H, Stepankova R, Kozakova H, Hudcovic T, Vannucci L, Tuckova L, et al. The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases. Cell Mol Immunol. 2011;8(2):110–120. doi: 10.1038/cmi.2010.67. PubMed DOI PMC

Yu JJ, Ruddy MJ, Conti HR, Boonanantanasarn K, Gaffen SL. The interleukin-17 receptor plays a gender-dependent role in host protection against Porphyromonas gingivalis-induced periodontal bone loss. Infect Immun. 2008;76(9):4206–4213. doi: 10.1128/IAI.01209-07. PubMed DOI PMC

O'Connor W, Jr, Kamanaka M, Booth CJ, Town T, Nakae S, Iwakura Y, et al. A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat Immunol. 2009;10(6):603–609. doi: 10.1038/ni.1736. PubMed DOI PMC

Tang C, Kakuta S, Shimizu K, Kadoki M, Kamiya T, Shimazu T, et al. Suppression of IL-17F, but not of IL-17A, provides protection against colitis by inducing Treg cells through modification of the intestinal microbiota. Nat Immunol. 2018;19(7):755–765. doi: 10.1038/s41590-018-0134-y. PubMed DOI

Dubin PJ, Kolls JK. IL-23 mediates inflammatory responses to mucoid Pseudomonas aeruginosa lung infection in mice. Am J Physiol Lung Cell Mol Physiol. 2007;292(2):L519–L528. doi: 10.1152/ajplung.00312.2006. PubMed DOI PMC

Dunne A, Ross PJ, Pospisilova E, Masin J, Meaney A, Sutton CE, et al. Inflammasome activation by adenylate cyclase toxin directs Th17 responses and protection against Bordetella pertussis. J Immunol. 2010;185(3):1711–1719. doi: 10.4049/jimmunol.1000105. PubMed DOI

Aujla SJ, Chan YR, Zheng M, Fei M, Askew DJ, Pociask DA, et al. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat Med. 2008;14(3):275–281. doi: 10.1038/nm1710. PubMed DOI PMC

Caruso R, Fina D, Paoluzi OA, Del Vecchio BG, Stolfi C, Rizzo A, et al. IL-23-mediated regulation of IL-17 production in Helicobacter pylori-infected gastric mucosa. Eur J Immunol. 2008;38(2):470–478. doi: 10.1002/eji.200737635. PubMed DOI

Cai Y, Shen X, Ding C, Qi C, Li K, Li X, et al. Pivotal role of dermal IL-17-producing gammadelta T cells in skin inflammation. Immunity. 2011;35(4):596–610. doi: 10.1016/j.immuni.2011.08.001. PubMed DOI PMC

Rizzo HL, Kagami S, Phillips KG, Kurtz SE, Jacques SL, Blauvelt A. IL-23-mediated psoriasis-like epidermal hyperplasia is dependent on IL-17A. J Immunol. 2011;186(3):1495–1502. doi: 10.4049/jimmunol.1001001. PubMed DOI

Watson AJ, Duckworth CA, Guan Y, Montrose MH. Mechanisms of epithelial cell shedding in the mammalian intestine and maintenance of barrier function. Ann N Y Acad Sci. 2009;1165:135–142. doi: 10.1111/j.1749-6632.2009.04027.x. PubMed DOI

Peltonen S, Riehokainen J, Pummi K, Peltonen J. Tight junction components occludin, ZO-1, and claudin-1, -4 and -5 in active and healing psoriasis. Br J Dermatol. 2007;156(3):466–472. doi: 10.1111/j.1365-2133.2006.07642.x. PubMed DOI

Richetta AG, Grassi S, Moliterni E, Chello C, Calvieri C, Carnevale R, et al. Increased intestinal barrier permeability in patients with moderate to severe plaque-type psoriasis. J Dermatol. 2020;47(10):e366–e368. doi: 10.1111/1346-8138.15361. PubMed DOI

Ajamian M, Steer D, Rosella G, Gibson PR. Serum zonulin as a marker of intestinal mucosal barrier function: May not be what it seems. PLoS ONE. 2019;14(1):e0210728. doi: 10.1371/journal.pone.0210728. PubMed DOI PMC

Sikora M, Stec A, Chrabaszcz M, Waskiel-Burnat A, Zaremba M, Olszewska M, et al. Intestinal fatty acid binding protein, a biomarker of intestinal barrier, is associated with severity of psoriasis. J Clin Med. 2019;8(7):1021. doi: 10.3390/jcm8071021. PubMed DOI PMC

Sikora M, Chrabaszcz M, Waskiel-Burnat A, Rakowska A, Olszewska M, Rudnicka L. Claudin-3 - a new intestinal integrity marker in patients with psoriasis: association with disease severity. J Eur Acad Dermatol Venereol. 2019;33(10):1907–1912. doi: 10.1111/jdv.15700. PubMed DOI

Linehan JL, Harrison OJ, Han SJ, Byrd AL, Vujkovic-Cvijin I, Villarino AV, et al. Non-classical immunity controls microbiota impact on skin immunity and tissue repair. Cell. 2018;172(4):784–96 e18. doi: 10.1016/j.cell.2017.12.033. PubMed DOI PMC

Naik S, Bouladoux N, Linehan JL, Han SJ, Harrison OJ, Wilhelm C, et al. Commensal-dendritic-cell interaction specifies a unique protective skin immune signature. Nature. 2015;520(7545):104–108. doi: 10.1038/nature14052. PubMed DOI PMC

Chen B, Chen H, Shu X, Yin Y, Li J, Qin J, et al. Presence of segmented filamentous bacteria in human children and its potential role in the modulation of human gut immunity. Front Microbiol. 2018;9:1403. doi: 10.3389/fmicb.2018.01403. PubMed DOI PMC

Stepankova R, Sinkora J, Hudcovic T, Kozakova H, Tlaskalova-Hogenova H. Differences in development of lymphocyte subpopulations from gut-associated lymphatic tissue (GALT) of germfree and conventional rats: effect of aging. Folia Microbiol (Praha) 1998;43(5):531–534. doi: 10.1007/BF02820814. PubMed DOI

Wu HJ, Ivanov II, Darce J, Hattori K, Shima T, Umesaki Y, et al. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity. 2010;32(6):815–827. doi: 10.1016/j.immuni.2010.06.001. PubMed DOI PMC

Stepankova R, Powrie F, Kofronova O, Kozakova H, Hudcovic T, Hrncir T, et al. Segmented filamentous bacteria in a defined bacterial cocktail induce intestinal inflammation in SCID mice reconstituted with CD45RBhigh CD4+ T cells. Inflamm Bowel Dis. 2007;13(10):1202–1211. doi: 10.1002/ibd.20221. PubMed DOI

Chaonan Sun LC, Huan Yang, Hongjiang Sun, Zhen Xie, Bei Zhao, Xuemei Jiang, Bi Qin, Zhu Shen. Involvement of Gut Microbiota in the Development of Psoriasis Vulgaris. 2020. PubMed PMC

Kawashima K, Misawa H, Moriwaki Y, Fujii YX, Fujii T, Horiuchi Y, et al. Ubiquitous expression of acetylcholine and its biological functions in life forms without nervous systems. Life Sci. 2007;80(24–25):2206–2209. doi: 10.1016/j.lfs.2007.01.059. PubMed DOI

Masson F, Talon R, Montel MC. Histamine and tyramine production by bacteria from meat products. Int J Food Microbiol. 1996;32(1–2):199–207. doi: 10.1016/0168-1605(96)01104-X. PubMed DOI

Thomas CM, Hong T, van Pijkeren JP, Hemarajata P, Trinh DV, Hu W, et al. Histamine derived from probiotic Lactobacillus reuteri suppresses TNF via modulation of PKA and ERK signaling. PLoS ONE. 2012;7(2):e31951. doi: 10.1371/journal.pone.0031951. PubMed DOI PMC

Neuman H, Debelius JW, Knight R, Koren O. Microbial endocrinology: the interplay between the microbiota and the endocrine system. FEMS Microbiol Rev. 2015;39(4):509–521. doi: 10.1093/femsre/fuu010. PubMed DOI

Omenetti S, Pizarro TT. The Treg/Th17 axis: a dynamic balance regulated by the gut microbiome. Front Immunol. 2015;6:639. doi: 10.3389/fimmu.2015.00639. PubMed DOI PMC

Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr. 1995;125(6):1401–1412. doi: 10.1093/jn/125.6.1401. PubMed DOI

Wu SE, Hashimoto-Hill S, Woo V, Eshleman EM, Whitt J, Engleman L, et al. Microbiota-derived metabolite promotes HDAC3 activity in the gut. Nature. 2020;586(7827):108–112. doi: 10.1038/s41586-020-2604-2. PubMed DOI PMC

Schwarz A, Bruhs A, Schwarz T. The short-chain fatty acid sodium butyrate functions as a regulator of the skin immune system. J Invest Dermatol. 2017;137(4):855–864. doi: 10.1016/j.jid.2016.11.014. PubMed DOI

Maslowski KM, Vieira AT, Ng A, Kranich J, Sierro F, Yu D, et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature. 2009;461(7268):1282–1286. doi: 10.1038/nature08530. PubMed DOI PMC

Drago F, Ciccarese G, Indemini E, Savarino V, Parodi A. Psoriasis and small intestine bacterial overgrowth. Int J Dermatol. 2018;57(1):112–113. doi: 10.1111/ijd.13797. PubMed DOI

McFadden J, Valdimarsson H, Fry L. Cross-reactivity between streptococcal M surface antigen and human skin. Br J Dermatol. 1991;125(5):443–447. doi: 10.1111/j.1365-2133.1991.tb14769.x. PubMed DOI

Norrlind R. Psoriasis following infections with hemolytic streptococci. Acta Derm Venereol. 1950;30(1):64–72. PubMed

Perez-Lorenzo R, Zambrano-Zaragoza JF, Saul A, Jimenez-Zamudio L, Reyes-Maldonado E, Garcia-Latorre E. Autoantibodies to autologous skin in guttate and plaque forms of psoriasis and cross-reaction of skin antigens with streptococcal antigens. Int J Dermatol. 1998;37(7):524–531. doi: 10.1046/j.1365-4362.1998.00512.x. PubMed DOI

Sigurdardottir SL, Thorleifsdottir RH, Valdimarsson H, Johnston A. The association of sore throat and psoriasis might be explained by histologically distinctive tonsils and increased expression of skin-homing molecules by tonsil T cells. Clin Exp Immunol. 2013;174(1):139–151. doi: 10.1111/cei.12153. PubMed DOI PMC

Rudramurthy SM, Honnavar P, Chakrabarti A, Dogra S, Singh P, Handa S. Association of Malassezia species with psoriatic lesions. Mycoses. 2014;57(8):483–488. doi: 10.1111/myc.12186. PubMed DOI

Tomi NS, Kranke B, Aberer E. Staphylococcal toxins in patients with psoriasis, atopic dermatitis, and erythroderma, and in healthy control subjects. J Am Acad Dermatol. 2005;53(1):67–72. doi: 10.1016/j.jaad.2005.02.034. PubMed DOI

Alekseyenko AV, Perez-Perez GI, De Souza A, Strober B, Gao Z, Bihan M, et al. Community differentiation of the cutaneous microbiota in psoriasis. Microbiome. 2013;1(1):31. doi: 10.1186/2049-2618-1-31. PubMed DOI PMC

Fahlen A, Engstrand L, Baker BS, Powles A, Fry L. Comparison of bacterial microbiota in skin biopsies from normal and psoriatic skin. Arch Dermatol Res. 2012;304(1):15–22. doi: 10.1007/s00403-011-1189-x. PubMed DOI

Tett A, Pasolli E, Farina S, Truong DT, Asnicar F, Zolfo M, et al. Unexplored diversity and strain-level structure of the skin microbiome associated with psoriasis. NPJ Biofilms Microbiomes. 2017;3:14. doi: 10.1038/s41522-017-0022-5. PubMed DOI PMC

Bukin YS, Galachyants YP, Morozov IV, Bukin SV, Zakharenko AS, Zemskaya TI. The effect of 16S rRNA region choice on bacterial community metabarcoding results. Sci Data. 2019;6:190007. doi: 10.1038/sdata.2019.7. PubMed DOI PMC

Castelino M, Eyre S, Moat J, Fox G, Martin P, Ho P, et al. Optimisation of methods for bacterial skin microbiome investigation: primer selection and comparison of the 454 versus MiSeq platform. BMC Microbiol. 2017;17(1):23. doi: 10.1186/s12866-017-0927-4. PubMed DOI PMC

Willis C, Desai D, LaRoche J. Influence of 16S rRNA variable region on perceived diversity of marine microbial communities of the Northern North Atlantic. FEMS Microbiol Lett. 2019 doi: 10.1093/femsle/fnz152. PubMed DOI PMC

Yang B, Wang Y, Qian PY. Sensitivity and correlation of hypervariable regions in 16S rRNA genes in phylogenetic analysis. BMC Bioinform. 2016;17:135. doi: 10.1186/s12859-016-0992-y. PubMed DOI PMC

Conlan S, Kong HH, Segre JA. Species-level analysis of DNA sequence data from the NIH human microbiome project. PLoS ONE. 2012;7(10):e47075. doi: 10.1371/journal.pone.0047075. PubMed DOI PMC

Jo JH, Kennedy EA, Kong HH. Research techniques made simple: bacterial 16S ribosomal RNA gene sequencing in cutaneous research. J Invest Dermatol. 2016;136(3):e23–e27. doi: 10.1016/j.jid.2016.01.005. PubMed DOI PMC

Meisel JS, Hannigan GD, Tyldsley AS, SanMiguel AJ, Hodkinson BP, Zheng Q, et al. Skin microbiome surveys are strongly influenced by experimental design. J Invest Dermatol. 2016;136(5):947–956. doi: 10.1016/j.jid.2016.01.016. PubMed DOI PMC

Grice EA, Kong HH, Renaud G, Young AC, Program NCS, Bouffard GG, et al. A diversity profile of the human skin microbiota. Genome Res. 2008;18(7):1043–1050. doi: 10.1101/gr.075549.107. PubMed DOI PMC

Jumpstart Consortium Human Microbiome Project Data Generation Working G. Evaluation of 16S rDNA-based community profiling for human microbiome research. PLoS One. 2012;7(6):e39315. PubMed PMC

Teng F, Darveekaran Nair SS, Zhu P, Li S, Huang S, Li X, et al. Impact of DNA extraction method and targeted 16S-rRNA hypervariable region on oral microbiota profiling. Sci Rep. 2018;8(1):16321. doi: 10.1038/s41598-018-34294-x. PubMed DOI PMC

Paulino LC, Tseng CH, Strober BE, Blaser MJ. Molecular analysis of fungal microbiota in samples from healthy human skin and psoriatic lesions. J Clin Microbiol. 2006;44(8):2933–2941. doi: 10.1128/JCM.00785-06. PubMed DOI PMC

Takemoto A, Cho O, Morohoshi Y, Sugita T, Muto M. Molecular characterization of the skin fungal microbiome in patients with psoriasis. J Dermatol. 2015;42(2):166–170. doi: 10.1111/1346-8138.12739. PubMed DOI

Jagielski T, Rup E, Ziolkowska A, Roeske K, Macura AB, Bielecki J. Distribution of Malassezia species on the skin of patients with atopic dermatitis, psoriasis, and healthy volunteers assessed by conventional and molecular identification methods. BMC Dermatol. 2014;14:3. doi: 10.1186/1471-5945-14-3. PubMed DOI PMC

Gupta AK, Kohli Y, Summerbell RC, Faergemann J. Quantitative culture of Malassezia species from different body sites of individuals with or without dermatoses. Med Mycol. 2001;39(3):243–251. doi: 10.1080/mmy.39.3.243.251. PubMed DOI

Amaya M, Tajima M, Okubo Y, Sugita T, Nishikawa A, Tsuboi R. Molecular analysis of Malassezia microflora in the lesional skin of psoriasis patients. J Dermatol. 2007;34(9):619–624. doi: 10.1111/j.1346-8138.2007.00343.x. PubMed DOI

Chang HW, Yan D, Singh R, Liu J, Lu X, Ucmak D, et al. Alteration of the cutaneous microbiome in psoriasis and potential role in Th17 polarization. Microbiome. 2018;6(1):154. doi: 10.1186/s40168-018-0533-1. PubMed DOI PMC

Hurabielle C, Link VM, Bouladoux N, Han SJ, Merrill ED, Lightfoot YL, et al. Immunity to commensal skin fungi promotes psoriasiform skin inflammation. Proc Natl Acad Sci U S A. 2020;117(28):16465–16474. doi: 10.1073/pnas.2003022117. PubMed DOI PMC

Mosca A, Leclerc M, Hugot JP. Gut microbiota diversity and human diseases: should we reintroduce key predators in our ecosystem? Front Microbiol. 2016;7:455. doi: 10.3389/fmicb.2016.00455. PubMed DOI PMC

Fredricks DN, Fiedler TL, Marrazzo JM. Molecular identification of bacteria associated with bacterial vaginosis. N Engl J Med. 2005;353(18):1899–1911. doi: 10.1056/NEJMoa043802. PubMed DOI

Srinivasan S, Hoffman NG, Morgan MT, Matsen FA, Fiedler TL, Hall RW, et al. Bacterial communities in women with bacterial vaginosis: high resolution phylogenetic analyses reveal relationships of microbiota to clinical criteria. PLoS ONE. 2012;7(6):e37818. doi: 10.1371/journal.pone.0037818. PubMed DOI PMC

Shapiro J, Cohen NA, Shalev V, Uzan A, Koren O, Maharshak N. Psoriatic patients have a distinct structural and functional fecal microbiota compared with controls. J Dermatol. 2019;46(7):595–603. doi: 10.1111/1346-8138.14933. PubMed DOI

Tan L, Zhao S, Zhu W, Wu L, Li J, Shen M, et al. The Akkermansia muciniphila is a gut microbiota signature in psoriasis. Exp Dermatol. 2018;27(2):144–149. doi: 10.1111/exd.13463. PubMed DOI

Reiss Z, Rob F, Kolar M, Schierova D, Kreisinger J, Jackova Z, et al. Skin microbiota signature distinguishes IBD patients and reflects skin adverse events during anti-TNF therapy. Front Cell Infect Microbiol. 2022;12:1064537. doi: 10.3389/fcimb.2022.1064537. PubMed DOI PMC

Yegorov S, Babenko D, Kozhakhmetov S, Akhmaltdinova L, Kadyrova I, Nurgozhina A, et al. Psoriasis is associated with elevated gut IL-1alpha and intestinal microbiome alterations. Front Immunol. 2020;11:571319. doi: 10.3389/fimmu.2020.571319. PubMed DOI PMC

Yeh NL, Hsu CY, Tsai TF, Chiu HY. Gut microbiome in psoriasis is perturbed differently during secukinumab and ustekinumab therapy and associated with response to treatment. Clin Drug Investig. 2019;39(12):1195–1203. doi: 10.1007/s40261-019-00849-7. PubMed DOI

Demirci M, Tokman HB, Uysal HK, Demiryas S, Karakullukcu A, Saribas S, et al. Reduced Akkermansia muciniphila and Faecalibacterium prausnitzii levels in the gut microbiota of children with allergic asthma. Allergol Immunopathol (Madr) 2019;47(4):365–371. doi: 10.1016/j.aller.2018.12.009. PubMed DOI

Pittayanon R, Lau JT, Leontiadis GI, Tse F, Yuan Y, Surette M, et al. Differences in gut microbiota in patients with vs without inflammatory bowel diseases: a systematic review. Gastroenterology. 2020;158(4):930–46 e1. doi: 10.1053/j.gastro.2019.11.294. PubMed DOI

Eppinga H, Sperna Weiland CJ, Thio HB, van der Woude CJ, Nijsten TE, Peppelenbosch MP, et al. Similar depletion of protective Faecalibacterium prausnitzii in psoriasis and inflammatory bowel disease, but not in hidradenitis suppurativa. J Crohns Colitis. 2016;10(9):1067–1075. doi: 10.1093/ecco-jcc/jjw070. PubMed DOI

Fritz JV, Desai MS, Shah P, Schneider JG, Wilmes P. From meta-omics to causality: experimental models for human microbiome research. Microbiome. 2013;1(1):14. doi: 10.1186/2049-2618-1-14. PubMed DOI PMC

Okada K, Matsushima Y, Mizutani K, Yamanaka K. The role of gut microbiome in psoriasis: oral administration of Staphylococcus aureus and Streptococcus danieliae exacerbates skin inflammation of imiquimod-induced psoriasis-like dermatitis. Int J Mol Sci. 2020;21(9):3303. doi: 10.3390/ijms21093303. PubMed DOI PMC

Stehlikova Z, Kostovcikova K, Kverka M, Rossmann P, Dvorak J, Novosadova I, et al. Crucial role of microbiota in experimental psoriasis revealed by a gnotobiotic mouse model. Front Microbiol. 2019;10:236. doi: 10.3389/fmicb.2019.00236. PubMed DOI PMC

Heissigerova J, Seidler Stangova P, Klimova A, Svozilkova P, Hrncir T, Stepankova R, et al. The microbiota determines susceptibility to experimental autoimmune uveoretinitis. J Immunol Res. 2016;2016:5065703. doi: 10.1155/2016/5065703. PubMed DOI PMC

Garcia-Collinot G, Madrigal-Santillan EO, Martinez-Bencomo MA, Carranza-Muleiro RA, Jara LJ, Vera-Lastra O, et al. Effectiveness of Saccharomyces boulardii and metronidazole for small intestinal bacterial overgrowth in systemic sclerosis. Dig Dis Sci. 2020;65(4):1134–1143. doi: 10.1007/s10620-019-05830-0. PubMed DOI

Soifer LO, Peralta D, Dima G, Besasso H. Comparative clinical efficacy of a probiotic vs. an antibiotic in the treatment of patients with intestinal bacterial overgrowth and chronic abdominal functional distension: a pilot study. Acta Gastroenterol Latinoam. 2010;40(4):323–7. PubMed

Zakostelska Z, Malkova J, Klimesova K, Rossmann P, Hornova M, Novosadova I, et al. Intestinal microbiota promotes psoriasis-like skin inflammation by enhancing Th17 response. PLoS ONE. 2016;11(7):e0159539. doi: 10.1371/journal.pone.0159539. PubMed DOI PMC

Zanvit P, Konkel JE, Jiao X, Kasagi S, Zhang D, Wu R, et al. Antibiotics in neonatal life increase murine susceptibility to experimental psoriasis. Nat Commun. 2015;6:8424. doi: 10.1038/ncomms9424. PubMed DOI PMC

Zhang M, Jiang Z, Li D, Jiang D, Wu Y, Ren H, et al. Oral antibiotic treatment induces skin microbiota dysbiosis and influences wound healing. Microb Ecol. 2015;69(2):415–421. doi: 10.1007/s00248-014-0504-4. PubMed DOI

Baba H, Masuyama A, Yoshimura C, Aoyama Y, Takano T, Ohki K. Oral intake of Lactobacillus helveticus-fermented milk whey decreased transepidermal water loss and prevented the onset of sodium dodecylsulfate-induced dermatitis in mice. Biosci Biotechnol Biochem. 2010;74(1):18–23. doi: 10.1271/bbb.90370. PubMed DOI

Gueniche A, Benyacoub J, Philippe D, Bastien P, Kusy N, Breton L, et al. Lactobacillus paracasei CNCM I-2116 (ST11) inhibits substance P-induced skin inflammation and accelerates skin barrier function recovery in vitro. Eur J Dermatol. 2010;20(6):731–737. PubMed

Ogawa M, Saiki A, Matsui Y, Tsuchimoto N, Nakakita Y, Takata Y, et al. Effects of oral intake of heat-killed Lactobacillus brevis SBC8803 (SBL88) on dry skin conditions: A randomized, double-blind, placebo-controlled study. Exp Ther Med. 2016;12(6):3863–3872. doi: 10.3892/etm.2016.3862. PubMed DOI PMC

Kozakova H, Schwarzer M, Tuckova L, Srutkova D, Czarnowska E, Rosiak I, et al. Colonization of germ-free mice with a mixture of three lactobacillus strains enhances the integrity of gut mucosa and ameliorates allergic sensitization. Cell Mol Immunol. 2016;13(2):251–262. doi: 10.1038/cmi.2015.09. PubMed DOI PMC

Zakostelska Z, Kverka M, Klimesova K, Rossmann P, Mrazek J, Kopecny J, et al. Lysate of probiotic Lactobacillus casei DN-114 001 ameliorates colitis by strengthening the gut barrier function and changing the gut microenvironment. PLoS ONE. 2011;6(11):e27961. doi: 10.1371/journal.pone.0027961. PubMed DOI PMC

Jenneck C, Novak N. The safety and efficacy of alefacept in the treatment of chronic plaque psoriasis. Ther Clin Risk Manag. 2007;3(3):411–420. PubMed PMC

Dai C, Jiang M, Sun MJ. Letter: increased risk of developing Crohn's disease or ulcerative colitis in 17 018 patients while under treatment with anti-TNFalpha agents, particularly etanercept, for autoimmune diseases other than IBD. Aliment Pharmacol Ther. 2019;50(7):834–835. doi: 10.1111/apt.15460. PubMed DOI

Gall JS, Kalb RE. Infliximab for the treatment of plaque psoriasis. Biologics. 2008;2(1):115–124. PubMed PMC

Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum. 2010;40(3):233–240. doi: 10.1016/j.semarthrit.2010.04.003. PubMed DOI

Fiorino G, Danese S, Pariente B, Allez M. Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-alpha agents. Autoimmun Rev. 2014;13(1):15–19. doi: 10.1016/j.autrev.2013.06.005. PubMed DOI

Warren RB, Smith CH, Yiu ZZN, Ashcroft DM, Barker J, Burden AD, et al. Differential drug survival of biologic therapies for the treatment of psoriasis: a Prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR) J Invest Dermatol. 2015;135(11):2632–2640. doi: 10.1038/jid.2015.208. PubMed DOI

Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–1072. doi: 10.1016/j.jaad.2018.11.057. PubMed DOI

Ten Bergen LL, Petrovic A, Krogh Aarebrot A, Appel S. The TNF/IL-23/IL-17 axis-Head-to-head trials comparing different biologics in psoriasis treatment. Scand J Immunol. 2020;92(4):e12946. PubMed

Naik PP. Adverse effects of anti-interleukin-23 agents employed in patients with psoriasis: a systematic review. Dermatology. 2022;238(5):886–896. doi: 10.1159/000524199. PubMed DOI

Loesche MA, Farahi K, Capone K, Fakharzadeh S, Blauvelt A, Duffin KC, et al. Longitudinal study of the psoriasis-associated skin microbiome during therapy with ustekinumab in a randomized phase 3b clinical trial. J Invest Dermatol. 2018;138(9):1973–1981. doi: 10.1016/j.jid.2018.03.1501. PubMed DOI

Dei-Cas I, Giliberto F, Luce L, Dopazo H, Penas-Steinhardt A. Metagenomic analysis of gut microbiota in non-treated plaque psoriasis patients stratified by disease severity: development of a new Psoriasis-Microbiome Index. Sci Rep. 2020;10(1):12754. doi: 10.1038/s41598-020-69537-3. PubMed DOI PMC

Koike Y, Kuwatsuka S, Nishimoto K, Motooka D, Murota H. Skin mycobiome of psoriasis patients is retained during treatment with TNF and IL-17 inhibitors. Int J Mol Sci. 2020;21(11):3892. doi: 10.3390/ijms21113892. PubMed DOI PMC

Kalliomaki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet. 2001;357(9262):1076–1079. doi: 10.1016/S0140-6736(00)04259-8. PubMed DOI

Pandey KR, Naik SR, Vakil BV. Probiotics, prebiotics and synbiotics—a review. J Food Sci Technol. 2015;52(12):7577–7587. doi: 10.1007/s13197-015-1921-1. PubMed DOI PMC

Volkova LA, Khalif IL, Kabanova IN. Impact of the impaired intestinal microflora on the course of acne vulgaris. Klin Med (Mosk) 2001;79(6):39–41. PubMed

Ogawa M, Saiki A, Matsui Y, Tsuchimoto N, Nakakita Y, Takata Y, et al. Effects of oral intake of heat-killed Lactobacillus brevis SBC8803 (SBL88™) on dry skin conditions: a randomized, double-blind, placebo-controlled study. Exp Ther Med. 2016;12(6):3863–3872. doi: 10.3892/etm.2016.3862. PubMed DOI PMC

Evelo Biosciences Reports Positive EDP1815 Interim Clinical Data in Psoriasis Patients at Low Dose in Ongoing Phase 1b Tria. Retrieved from http://ir.evelobio.com/newsreleases/news-releasedetails/evelo-biosciencesreports-positive-edp1815- interim-clinical-data. 2019.

Groeger D, O'Mahony L, Murphy EF, Bourke JF, Dinan TG, Kiely B, et al. Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut. Gut Microbes. 2013;4(4):325–339. doi: 10.4161/gmic.25487. PubMed DOI PMC

Navarro-Lopez V, Martinez-Andres A, Ramirez-Bosca A, Ruzafa-Costas B, Nunez-Delegido E, Carrion-Gutierrez MA, et al. Efficacy and safety of oral administration of a mixture of probiotic strains in patients with psoriasis: a randomized controlled clinical trial. Acta Derm Venereol. 2019;99(12):1078–1084. PubMed

Kragsnaes MS, Kjeldsen J, Horn HC, Munk HL, Pedersen FM, Holt HM, et al. Efficacy and safety of faecal microbiota transplantation in patients with psoriatic arthritis: protocol for a 6-month, double-blind, randomised, placebo-controlled trial. BMJ Open. 2018;8(4):e019231. doi: 10.1136/bmjopen-2017-019231. PubMed DOI PMC

Yin G, Li JF, Sun YF, Ding X, Zeng JQ, Zhang T, et al. Fecal microbiota transplantation as a novel therapy for severe psoriasis. Zhonghua Nei Ke Za Zhi. 2019;58(10):782–785. PubMed

Oh J, Byrd AL, Park M, Kong HH, Segre JA, Program NCS. Temporal stability of the human skin microbiome. Cell. 2016;165(4):854–866. doi: 10.1016/j.cell.2016.04.008. PubMed DOI PMC

Callewaert C, Knödlseder N, Karoglan A, Güell M, Paetzold B. Skin microbiome transplantation and manipulation: Current state of the art. Comput Struct Biotechnol J. 2021;19:624–631. doi: 10.1016/j.csbj.2021.01.001. PubMed DOI PMC

Christophers E. Psoriasis—epidemiology and clinical spectrum. Clin Exp Dermatol. 2001;26(4):314–320. doi: 10.1046/j.1365-2230.2001.00832.x. PubMed DOI

Alinaghi F, Tekin HG, Burisch J, Wu JJ, Thyssen JP, Egeberg A. Global prevalence and bidirectional association between psoriasis and inflammatory bowel disease—a systematic review and meta-analysis. J Crohns Colitis. 2020;14(3):351–360. doi: 10.1093/ecco-jcc/jjz152. PubMed DOI

Coufal S, Galanova N, Bajer L, Gajdarova Z, Schierova D, Jiraskova Zakostelska Z, et al. Inflammatory bowel disease types differ in markers of inflammation, gut barrier and in specific anti-bacterial response. Cells. 2019;8(7):719. doi: 10.3390/cells8070719. PubMed DOI PMC

Schierova D, Roubalova R, Kolar M, Stehlikova Z, Rob F, Jackova Z, et al. Fecal microbiome changes and specific anti-bacterial response in patients with IBD during anti-TNF therapy. Cells. 2021;10(11):3188. doi: 10.3390/cells10113188. PubMed DOI PMC

Tang H, Jin X, Li Y, Jiang H, Tang X, Yang X, et al. A large-scale screen for coding variants predisposing to psoriasis. Nat Genet. 2014;46(1):45–50. doi: 10.1038/ng.2827. PubMed DOI

Cotsapas C, Voight BF, Rossin E, Lage K, Neale BM, Wallace C, et al. Pervasive sharing of genetic effects in autoimmune disease. PLoS Genet. 2011;7(8):e1002254. doi: 10.1371/journal.pgen.1002254. PubMed DOI PMC

Eppinga H, Poortinga S, Thio HB, Nijsten TEC, Nuij V, van der Woude CJ, et al. Prevalence and phenotype of concurrent psoriasis and inflammatory bowel disease. Inflamm Bowel Dis. 2017;23(10):1783–1789. doi: 10.1097/MIB.0000000000001169. PubMed DOI

Triantafillidis JK, Malgarinos G. Severe psoriasis preceding diagnosis of large bowel Crohn's disease for 15 years. J Crohns Colitis. 2013;7(2):e80. doi: 10.1016/j.crohns.2012.07.014. PubMed DOI

Juzlova K, Votrubova J, Dzambova M, Gopfertova D, Hercogova J, Smerhovsky Z. Gastrointestinal comorbidities in patients with psoriasis in the Czech Republic: The results of 189 patients with psoriasis and 378 controls. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016;160(1):100–105. doi: 10.5507/bp.2015.048. PubMed DOI

Lolli E, Saraceno R, Calabrese E, Ascolani M, Scarozza P, Chiricozzi A, et al. Psoriasis phenotype in inflammatory bowel disease: a case-control prospective study. J Crohns Colitis. 2015;9(9):699–707. doi: 10.1093/ecco-jcc/jjv068. PubMed DOI

Nehring P, Przybyłkowski A. Is psoriasis treatment a risk factor for inflammatory bowel disease? Pharm Med. 2020;34:257–262. doi: 10.1007/s40290-020-00340-1. PubMed DOI PMC

Vlachos C, Gaitanis G, Katsanos KH, Christodoulou DK, Tsianos E, Bassukas ID. Psoriasis and inflammatory bowel disease: links and risks. Psoriasis (Auckland, NZ) 2016;6:73. PubMed PMC

Mocci G, Marzo M, Papa A, Armuzzi A, Guidi L. Dermatological adverse reactions during anti-TNF treatments: Focus on inflammatory bowel disease. J Crohns Colitis. 2013;7(10):769–779. doi: 10.1016/j.crohns.2013.01.009. PubMed DOI

Fiorino G, Danese S, Pariente B, Allez M. Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-alpha agents. Autoimmun Rev. 2014;13(1):15–19. doi: 10.1016/j.autrev.2013.06.005. PubMed DOI

Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatolog Treat. 2009;20(2):100–108. doi: 10.1080/09546630802441234. PubMed DOI

Korzenik J, Larsen MD, Nielsen J, Kjeldsen J, Norgard BM. Increased risk of developing Crohn's disease or ulcerative colitis in 17 018 patients while under treatment with anti-TNFalpha agents, particularly etanercept, for autoimmune diseases other than inflammatory bowel disease. Aliment Pharmacol Ther. 2019;50(3):289–294. doi: 10.1111/apt.15370. PubMed DOI

Fiorino G, Allez M, Malesci A, Danese S. Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease. Aliment Pharm Ther. 2009;29(9):921–927. doi: 10.1111/j.1365-2036.2009.03955.x. PubMed DOI

Rahier JF, Buche S, Peyrin-Biroulet L, Bouhnik Y, Duclos B, Louis E, et al. Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin Gastroenterol Hepatol. 2010;8(12):1048–1055. doi: 10.1016/j.cgh.2010.07.022. PubMed DOI

Pugliese D, Guidi L, Ferraro PM, Marzo M, Felice C, Celleno L, et al. Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study. Aliment Pharm Ther. 2015;42(7):880–888. doi: 10.1111/apt.13352. PubMed DOI

Rahier JF, Buche S, Peyrin-Biroulet L, Bouhnik Y, Duclos B, Louis E, et al. Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin Gastroenterol Hepatol. 2010;8(12):1048–1055. doi: 10.1016/j.cgh.2010.07.022. PubMed DOI

Collamer AN, Guerrero KT, Henning JS, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum. 2008;59(7):996–1001. doi: 10.1002/art.23835. PubMed DOI

Nigam GB, Bhandare AP, Antoniou GA, Limdi JK. Systematic review and meta-analysis of dermatological reactions in patients with inflammatory bowel disease treated with anti-tumour necrosis factor therapy. Eur J Gastroenterol Hepatol. 2021;33(3):346–357. doi: 10.1097/MEG.0000000000001917. PubMed DOI

Collamer AN, Guerrero KT, Henning JS, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthrit Rheum-Arthr. 2008;59(7):996–1001. doi: 10.1002/art.23835. PubMed DOI

Gatzka M. Skin under Tnf influence: how regulatory T cells work against macrophages in psoriasis. J Pathol. 2017;241(1):3–5. doi: 10.1002/path.4820. PubMed DOI

Jayasekera PSA, Walsh ML, Hurrell D, Parslew RAG. Case report of lichen planopilaris occurring in a pediatric patient receiving a tumor necrosis factor alpha inhibitor and a review of the literature. Pediatr Dermatol. 2016;33(2):E143–E146. doi: 10.1111/pde.12768. PubMed DOI

Andrade P, Lopes S, Albuquerque A, Osorio F, Pardal J, Macedo G. Oral lichen planus in IBD patients: a paradoxical adverse effect of anti-TNF-alpha therapy. Digest Dis Sci. 2015;60(9):2746–2749. doi: 10.1007/s10620-015-3680-2. PubMed DOI

Inoue-Nishimoto T, Hanafusa T, Igawa K, Azukizawa H, Yokomi A, Yokozeki H, et al. Possible association of anti-tumor necrosis factor-alpha antibody therapy with the development of scleroderma-like changes with lichen planus. Eur J Dermatol. 2015;25(5):513–515. doi: 10.1684/ejd.2015.2631. PubMed DOI

Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheu. 2010;40(3):233–240. doi: 10.1016/j.semarthrit.2010.04.003. PubMed DOI

Furue K, Ito T, Tsuji G, Kadono T, Nakahara T, Furue M. Autoimmunity and autoimmune co-morbidities in psoriasis. Immunology. 2018;154(1):21–27. doi: 10.1111/imm.12891. PubMed DOI PMC

Wlodarczyk M, Sobolewska A, Wojcik B, Loga K, Fichna J, Wisniewska-Jarosinska M. Correlations between skin lesions induced by anti-tumor necrosis factor-alpha and selected cytokines in Crohn's disease patients. World J Gastroentero. 2014;20(22):7019–7026. doi: 10.3748/wjg.v20.i22.7019. PubMed DOI PMC

Tillack C, Ehmann LM, Friedrich M, Laubender RP, Papay P, Vogelsang H, et al. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-gamma-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut. 2014;63(4):567–577. doi: 10.1136/gutjnl-2012-302853. PubMed DOI

Manichanh C, Rigottier-Gois L, Bonnaud E, Gloux K, Pelletier E, Frangeul L, et al. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut. 2006;55(2):205–211. doi: 10.1136/gut.2005.073817. PubMed DOI PMC

Fahlen A, Engstrand L, Baker BS, Powles A, Fry L. Comparison of bacterial microbiota in skin biopsies from normal and psoriatic skin. Arch Dermatol Res. 2012;304(1):15–22. doi: 10.1007/s00403-011-1189-x. PubMed DOI

Fry L, Baker BS, Powles AV, Fahlen A, Engstrand L. Is chronic plaque psoriasis triggered by microbiota in the skin? Brit J Dermatol. 2013;169(1):47–52. doi: 10.1111/bjd.12322. PubMed DOI

Kong HDH, Oh J, Deming C, Conlan S, Grice EA, Beatson MA, et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res. 2012;22(5):850–859. doi: 10.1101/gr.131029.111. PubMed DOI PMC

Dong J, Goldenberg G. New biologics in psoriasis: an update on IL-23 and IL-17 inhibitors. Cutis. 2017;99(2):123–127. PubMed

Fauny M, Moulin D, D'Amico F, Netter P, Petitpain N, Arnone D, et al. Paradoxical gastrointestinal effects of interleukin-17 blockers. Ann Rheum Dis. 2020;79(9):1132–1138. doi: 10.1136/annrheumdis-2020-217927. PubMed DOI

Huppler AR, Bishu S, Gaffen SL. Mucocutaneous candidiasis: the IL-17 pathway and implications for targeted immunotherapy. Arthritis Res Ther. 2012;14(4):217. doi: 10.1186/ar3893. PubMed DOI PMC

Elsner K, Holstein J, Hilke FJ, Blumenstock G, Walker B, Schmidt S, et al. Prevalence of candida species in psoriasis. Mycoses. 2022;65(2):247–254. doi: 10.1111/myc.13399. PubMed DOI

Targan SR, Feagan B, Vermeire S, Panaccione R, Melmed GY, Landers C, et al. A randomized, double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn's disease. Am J Gastroenterol. 2016;111(11):1599–1607. doi: 10.1038/ajg.2016.298. PubMed DOI

Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PD, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61(12):1693–1700. doi: 10.1136/gutjnl-2011-301668. PubMed DOI PMC

Reich K, Leonardi C, Langley RG, Warren RB, Bachelez H, Romiti R, et al. Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials. J Am Acad Dermatol. 2017;76(3):441–8 e2. doi: 10.1016/j.jaad.2016.10.027. PubMed DOI

Smith MK, Pai J, Panaccione R, Beck P, Ferraz JG, Jijon H. Crohn's-like disease in a patient exposed to anti-Interleukin-17 blockade (Ixekizumab) for the treatment of chronic plaque psoriasis: a case report. BMC Gastroenterol. 2019;19(1):162. doi: 10.1186/s12876-019-1067-0. PubMed DOI PMC

Nazarian A, Grin A, Wijeratne DT. Ixekizumab associated new-onset inflammatory bowel disease. ACG Case Rep J. 2020;7(2):e00316. doi: 10.14309/crj.0000000000000316. PubMed DOI PMC

Johnston RD, Logan RF. What is the peak age for onset of IBD? Inflamm Bowel Dis. 2008;14(Suppl 2):S4–5. doi: 10.1002/ibd.20545. PubMed DOI

Earley H, Lennon G, Balfe A, Coffey JC, Winter DC, O'Connell PR. The abundance of Akkermansia muciniphila and its relationship with sulphated colonic mucins in health and ulcerative colitis. Sci Rep. 2019;9(1):15683. doi: 10.1038/s41598-019-51878-3. PubMed DOI PMC

Zhang T, Li P, Wu X, Lu G, Marcella C, Ji X, et al. Alterations of Akkermansia muciniphila in the inflammatory bowel disease patients with washed microbiota transplantation. Appl Microbiol Biotechnol. 2020;104(23):10203–10215. doi: 10.1007/s00253-020-10948-7. PubMed DOI

Elmets CA, Lim HW, Stoff B, Connor C, Cordoro KM, Lebwohl M, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. J Am Acad Dermatol. 2019;81(3):775–804. doi: 10.1016/j.jaad.2019.04.042. PubMed DOI

Camela E, Potestio L, Fabbrocini G, Ruggiero A, Megna M. New frontiers in personalized medicine in psoriasis. Expert Opin Biol Ther. 2022;22(12):1431–1433. doi: 10.1080/14712598.2022.2113872. PubMed DOI